Boditech Med Inc.

KOSDAQ 206640.KQ

Boditech Med Inc. Free Cash Flow for the year ending December 31, 2023: USD 22.02 M

Boditech Med Inc. Free Cash Flow is USD 22.02 M for the year ending December 31, 2023, a 352.21% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Boditech Med Inc. Free Cash Flow for the year ending December 31, 2022 was USD 4.87 M, a -81.54% change year over year.
  • Boditech Med Inc. Free Cash Flow for the year ending December 31, 2021 was USD 26.38 M, a -28.79% change year over year.
  • Boditech Med Inc. Free Cash Flow for the year ending December 31, 2020 was USD 37.04 M, a 253.04% change year over year.
  • Boditech Med Inc. Free Cash Flow for the year ending December 31, 2019 was USD 10.49 M, a 626.85% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
KOSDAQ: 206640.KQ

Boditech Med Inc.

CEO Ui-Yeol Choe
IPO Date Sept. 1, 2015
Location South Korea
Headquarters 43, Geodudanji 1-gil
Employees 469
Sector Health Care
Industries
Description

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.

Similar companies

030720.KS

Dong Won Fisheries Co., Ltd.

USD 3.45

0.54%

StockViz Staff

January 15, 2025

Any question? Send us an email